The tumor microenvironment (TME) plays a vital role in tumorigenesis, progression, metastasis, and therapeutic resistance by dynamically interacting with cancer cells. TME serves as a sustained niche for cancer cells to proliferate and metastasize, which consists of extracellular matrix (ECM), secreted molecules, immune cells, and stromal cells. Besides, various cellular components in TME such as endothelial cells, fibroblasts, pericytes, adipocytes, and immune cells could modulate tumor growth and immune activity.
Recently researches regarding TME have identified new targets correlated with efficacy in cancer treatments, especially immunotherapy. The immune checkpoint blockades have yielded success in multiple kinds of solid tumors, notably the PD-1/PD-L1 axis. However, some other problems arise during the treatment. For example, the LRRC15+ myofibroblasts and myofibroblasts from subclusters 0 and 3 of type S1 cancer-associated fibroblasts (CAFs) are linked to drug resistance in cancer. Besides, directly targeting regulatory T cells (Tregs) in TME is considered as an alternative approach to reconstructing the anti-tumor immune response. Breast cancer and gastrointestinal cancer are two common tumors worldwide, which is indispensable to exploring the underlying mechanisms involved in the interaction among cells and the potential therapeutic targets related to TME.
This Research Topic aims to elucidate the interaction between TME and malignant cells, and the potential mechanisms that affect the immune response, immune escape, and immunotherapy resistance. We welcome the authors to submit Original Research and Review articles contributing to uncovering the new hallmarks involved in TME, cancer immunology, immunotherapy, drug resistance, and therapeutic strategies in breast and gastrointestinal cancer.
(1) Molecular mechanisms underlying the intercellular crosstalk among cells in TME
(2) Signaling pathways related to the immune response in TME
(3) Therapeutic approaches targeting intercellular interactions in TME
(4) New strategies to facilitate immunotherapy effects
(5) The role of infiltrating CAFs and immune cells in TME or cancer immunotherapy
(6) Tumor heterogeneity related to TME and immunotherapy
(7) Strategies to predict or overcome immunotherapy resistance
(8) TME reprogramming after immunotherapy
(9) Similarities, differences, and therapeutic outcomes of the TME
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
The tumor microenvironment (TME) plays a vital role in tumorigenesis, progression, metastasis, and therapeutic resistance by dynamically interacting with cancer cells. TME serves as a sustained niche for cancer cells to proliferate and metastasize, which consists of extracellular matrix (ECM), secreted molecules, immune cells, and stromal cells. Besides, various cellular components in TME such as endothelial cells, fibroblasts, pericytes, adipocytes, and immune cells could modulate tumor growth and immune activity.
Recently researches regarding TME have identified new targets correlated with efficacy in cancer treatments, especially immunotherapy. The immune checkpoint blockades have yielded success in multiple kinds of solid tumors, notably the PD-1/PD-L1 axis. However, some other problems arise during the treatment. For example, the LRRC15+ myofibroblasts and myofibroblasts from subclusters 0 and 3 of type S1 cancer-associated fibroblasts (CAFs) are linked to drug resistance in cancer. Besides, directly targeting regulatory T cells (Tregs) in TME is considered as an alternative approach to reconstructing the anti-tumor immune response. Breast cancer and gastrointestinal cancer are two common tumors worldwide, which is indispensable to exploring the underlying mechanisms involved in the interaction among cells and the potential therapeutic targets related to TME.
This Research Topic aims to elucidate the interaction between TME and malignant cells, and the potential mechanisms that affect the immune response, immune escape, and immunotherapy resistance. We welcome the authors to submit Original Research and Review articles contributing to uncovering the new hallmarks involved in TME, cancer immunology, immunotherapy, drug resistance, and therapeutic strategies in breast and gastrointestinal cancer.
(1) Molecular mechanisms underlying the intercellular crosstalk among cells in TME
(2) Signaling pathways related to the immune response in TME
(3) Therapeutic approaches targeting intercellular interactions in TME
(4) New strategies to facilitate immunotherapy effects
(5) The role of infiltrating CAFs and immune cells in TME or cancer immunotherapy
(6) Tumor heterogeneity related to TME and immunotherapy
(7) Strategies to predict or overcome immunotherapy resistance
(8) TME reprogramming after immunotherapy
(9) Similarities, differences, and therapeutic outcomes of the TME
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
